LAG3 Enrollment_Hubspot page size

Enrolling Until June 3rd, 2022

This screen will test your drug/agent using our validated multitarget humanized mouse model (BALB/c-hPD1/hPDL1/LAG3) and well-characterized humanized syngeneic CT26 tumor cell line for colorectal cancer (other cell lines available, please contact us to discuss). Our experienced researchers will collect tumor growth inhibition and body weight data. We will also provide subcutaneous tumor growth survival data and a final report. Optional endpoint analyses including tumor infiltrating lymphocyte by flow cytometry, serum cytokine analysis, and tissue sample collection are also available as an add-on service. Our dedicated team is here to provide you with customized R&D support, from study design to data interpretation. 

In Vivo Efficacy Testing of Various Drugs in Female BALB/c-hPD1/hPDL1/hLAG3 Mice Bearing CT26-hPDL1 Tumors 

LAG3 graph with border
  • No Minimum Enrollment 
  • Innovative Models: Use of a triple target mouse model and a well-established humanized cell line
  • Add-on Analyses Available: flow cytometry, serum analysis, tissue collection for IHC  
  • Customized R&D Support: study design, data interpretation, troubleshooting 
  • Enrollment is open until June 3rd, 2022, on a first-come, first-serve basis 

                                                                                                                 

Fill out this form and one of our team members will be in contact to discuss the study